Our website uses essential cookies and, with your consent, additional cookies to measure performance and improve our services. Cookie Policy.
You can change your choice at any time.
Tag
A breakthrough study reveals that osimertinib-induced cardiac dysfunction is driven by reversible sarcomere disarray via the GATA4-MYLK3-MYL2 signaling axis, suggesting that myosin activators could mitigate heart failure risk in lung cancer
This article reviews the latest evidence demonstrating improved overall survival with osimertinib combined with chemotherapy in first-line treatment of EGFR-mutated advanced non-small-cell lung cancer.
Neoadjuvant osimertinib, alone or with chemotherapy, significantly improves major pathological response rates in resectable EGFR-mutated NSCLC, offering a promising approach to enhance surgical outcomes and event-free survival with an accep